Furthermore, the recent development of BRAF inhibitors that do not trans-activate MAPK signalling termed ‘paradox-breakers' [42] may synergise with C012 and could offer a combination therapy purposed for BRAFWT melanomas. Here, BRAF is linked to melanoma.